Pancreatic Cancer Research

ResearcherVita-Salute San Raffaele UniversityActive in the last 2 years

Maria Gazouli

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3295-6811; OpenAlex author ID A5027706277. Sources: OpenAlex.

Their work

Papers
37 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
86
Papers, trials and grants by year

2012: 1 paper · 2013: 4 papers · 2014: none · 2015: 2 papers · 2016: 3 papers · 2017: 1 paper · 2018: 3 papers · 2019: 2 papers · 2020: 1 paper · 2021: 8 papers · 2022: 2 papers · 2023: 5 papers · 2024: 3 papers · 2025: 2 papers

Papers 37

  1. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  2. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  3. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  4. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  5. Dysbiosis Signature of Fecal Microbiota in Patients with Pancreatic Adenocarcinoma and Pancreatic Intraductal Papillary Mucinous Neoplasms. Last author DOI 10.3390/biomedicines12051040↗
  6. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  7. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  8. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  9. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  10. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  11. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Co-author DOI 10.1038/s41598-022-22973-9↗
  12. Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment? Co-author DOI 10.3390/ijms23073620↗
  13. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  14. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Co-author DOI 10.1038/s41598-021-87130-0↗
  15. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  16. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  17. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  18. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  19. Regulation of Hippo, TGFβ/SMAD, Wnt/β-Catenin, JAK/STAT, and NOTCH by Long Non-Coding RNAs in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.657965↗
  20. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  21. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Co-author DOI 10.1002/ijc.33004↗
  22. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  23. Association between genetic polymorphisms in long non-coding RNAs and pancreatic cancer risk. Last author DOI 10.3233/cbm-181959↗
  24. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Co-author DOI 10.1002/ijc.31047↗
  25. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/s41467-018-02942-5↗
  26. Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms. Co-author DOI 10.1093/carcin/bgx150↗
  27. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Co-author DOI 10.1038/srep43812↗
  28. Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1093/carcin/bgw080↗
  29. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗
  30. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Co-author DOI 10.18632/oncotarget.11041↗
  31. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.29590↗
  32. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Co-author DOI 10.1038/ng.3341↗
  33. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. Co-author DOI 10.1016/j.dld.2012.09.014↗
  34. MicroRNA gene polymorphisms in pancreatic cancer. Co-author DOI 10.1016/j.pan.2013.02.005↗
  35. Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Co-author DOI 10.1097/mpa.0b013e3182592ba7↗
  36. Lack of replication of seven pancreatic cancer susceptibility loci identified in two Asian populations. Co-author DOI 10.1158/1055-9965.epi-12-1182↗
  37. A review on the role of microRNA in biology, diagnosis, and treatment of pancreatic adenocarcinoma. Co-author DOI 10.1097/mpa.0b013e31823c9d21↗

Closest collaborators

The 25 strongest of 86 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Federico Canzian · 7 shared papers, 2013–2022 · strength 0.37
  2. Renata Talar‐Wojnarowska · 7 shared papers, 2013–2022 · strength 0.37
  3. Gabriele Capurso · 7 shared papers, 2013–2022 · strength 0.37
  4. Daniele Campa · 7 shared papers, 2013–2022 · strength 0.37
  5. Francesca Tavano · 6 shared papers, 2013–2022 · strength 0.34
  6. Pavel Souček · 6 shared papers, 2013–2022 · strength 0.31
  7. Raffaele Pezzilli · 6 shared papers, 2013–2022 · strength 0.31
  8. Beatrice Mohelníková-Duchoňová · 5 shared papers, 2013–2022 · strength 0.29
  9. John P. Neoptolemos · 5 shared papers, 2013–2022 · strength 0.29
  10. Theodoros A. Sidiropoulos · 1 shared paper, 2024 · strength 0.24
  11. Nikolaos F. Arkadopoulos · 1 shared paper, 2024 · strength 0.24
  12. Thilo Hackert · 4 shared papers, 2016–2021 · strength 0.23
  13. Oliver Strobel · 4 shared papers, 2016–2021 · strength 0.23
  14. Stamatios E Theocharis · 1 shared paper, 2022 · strength 0.20
  15. Stavros P. Papadakos · 1 shared paper, 2022 · strength 0.20
  16. Rita Teresa Lawlor · 3 shared papers, 2017–2022 · strength 0.19
  17. Ľudmila Vodičková · 4 shared papers, 2013–2022 · strength 0.19
  18. Giulia Martina Cavestro · 2 shared papers, 2021–2022 · strength 0.18
  19. Giuseppe Vanella · 2 shared papers, 2021–2022 · strength 0.18
  20. Manuel Gentiluomo · 2 shared papers, 2021–2022 · strength 0.18
  21. Casper H.J. van Eijck · 2 shared papers, 2021–2022 · strength 0.18
  22. Pavel Vodička · 4 shared papers, 2013–2021 · strength 0.18
  23. Martin Oliverius · 3 shared papers, 2016–2022 · strength 0.18
  24. Daniela Basso · 3 shared papers, 2013–2022 · strength 0.17
  25. Niccola Funel · 4 shared papers, 2013–2018 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.